When you look matters: the effect of assessment schedule on progression-free survival.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of the National Cancer Institute

• Publication date

  2007-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/DJK091PMID 17374832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  2005influential reference
• Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC).

  2004cited by this paper
• End points and United States Food and Drug Administration approval of oncology drugs.

  2003cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Tutorial in biostatistics methods for interval-censored data.

  1998cited by this paper
• Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model.

  1992cited by this paper
• Information Bounds and Nonparametric Maximum Likelihood Estimation

  1992cited by this paper
• The Empirical Distribution Function with Arbitrarily Grouped, Censored, and Truncated Data

  1976cited by this paper
• Experimental Survival Curves for Interval‐Censored Data

  1973cited by this paper

• Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review

  2025cites this paper
• The feasibility of using real world data as external control arms in oncology trials.

  2025cites this paper
• Concordance in assessments between investigators and blinded independent central review (BICR) in hematology oncology clinical trials: a meta-analysis

  2025cites this paper
• BLong-term results of branch retinal vein occlusion: 5-year follow-up

  2025cites this paper
• Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial

  2025cites this paper
• An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties

  2025cites this paper
• Journal of clinical epidemiology The Importance of Reporting CT Scan Intervals in Real-World Oncology Studies: A Simulation Analysis of Afatinib in Advanced-Stage Non-Small Cell Lung Cancer.

  2025cites this paper
• The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis

  2025cites this paper
• The Analysis of Thrombocytosis, Leukocytosis, Combination of Thrombocytosis and Leukocytosis to The Result of RECIST 1.1, Progression Free Survival, Stadium of Non Small Cell Lung Cancer Patients who Received Chemotherapy

  2025cites this paper
• Measurement error and bias in real-world oncology endpoints when constructing external control arms

  2024cites this paper
• Statistical approaches for component-wise censored composite endpoints

  2024cites this paper
• Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.

  2024cites this paper
• Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country

  2024cites this paper
• Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

  2024cites this paper
• Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials

  2023cites this paper
• Survival Analysis as a Basis to Test Hypotheses When Using Quantitative Ordinal Scale Disease Severity Data.

  2023cites this paper
• Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.

  2023cites this paper
• Estimated small dense low‐density lipoprotein cholesterol and nonalcoholic fatty liver disease in nonobese populations

  2023cites this paper
• Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.

  2023cites this paper
• Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR

  2023cites this paper
• Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany

  2023cites this paper
• Analysis of composite endpoints with component‐wise censoring in the presence of differential visit schedules

  2022influential citation
• Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review

  2022cites this paper
• The heterogeneity effect of surveillance intervals on progression free survival

  2022influential citation
• Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis

  2022cites this paper
• A proper statistical inference framework to compare clinical trial and real‐world progression‐free survival data

  2022cites this paper
• Journal of Stem Cell Research The Efficacy of Autologous Stem Cell Transplants to Treat High Risk Neuroblastoma

  2022cites this paper
• Multistate models for the natural history of cancer progression

  2022cites this paper
• Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

  2022cites this paper
• The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies

  2022cites this paper
• The Efficacy Of Autologous Stem Cell Transplants To Treat High Risk Neuroblastoma

  2022cites this paper
• Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review

  2021cites this paper
• Non-parametric Analysis of Interval-Censored Survival Data with Application to a Phase III Metastatic Colorectal Cancer Clinical Trial

  2021cites this paper
• How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments.

  2021cites this paper
• The frequency of assessment of progression in randomized oncology clinical trials

  2021cites this paper
• Progression‐free survival in oncological clinical studies: Assessment time bias and methods for its correction

  2021cites this paper
• Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database

  2021cites this paper
• Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study

  2021cites this paper
• Canine anal sac gland carcinoma with regional lymph node metastases treated with sacculectomy and lymphadenectomy: outcome and possible prognostic factors.

  2021cites this paper
• Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

  2021cites this paper
• Differential frequency in imaging‐based outcome measurement: Bias in real‐world oncology comparative‐effectiveness studies

  2021cites this paper
• Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model

  2021cites this paper
• The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.

  2021cites this paper
• Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

  2021cites this paper
• Nonparametric estimation in an illness‐death model with component‐wise censoring

  2021influential citation
• Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.

  2020cites this paper
• Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

  2020cites this paper
• Determination of hazard ratio for progression‐free survival considering the tumor assessment schedule in sample size calculation

  2020influential citation
• A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer

  2019cites this paper
• Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies

  2019cites this paper
• Criteria for Evaluation of Clinical Efficacy of Anticancer Medicines

  2019cites this paper
• Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

  2019cites this paper
• Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

  2019cites this paper
• The risk of cancer in statin users : a clinical and genetic approach

  2019cites this paper
• Interpretation klinischer Studiendaten zum Multiplen Myelom: Übertragung der Ergebnisse auf die klinische Praxis

  2019cites this paper
• Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet

  2019cites this paper
• Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.

  2019cites this paper
• Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

  2018cites this paper
• Kernel machine score test for pathway analysis in the presence of semi-competing risks

  2018cites this paper
• Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

  2018cites this paper
• Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology

  2018cites this paper
• Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

  2018cites this paper
• Sample size calculation for studies with grouped survival data

  2018cites this paper
• Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

  2017cites this paper
• Assessing Outcomes in Colorectal Cancer Surgery

  2017cites this paper
• How to Interpret Numeric Results in Publications

  2017cites this paper
• Clinical Trials in Ovarian Cancer

  2017cites this paper
• A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.

  2017cites this paper
• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

  2017cites this paper
• Mixture models for undiagnosed prevalent disease and interval‐censored incident disease: applications to a cohort assembled from electronic health records

  2017cites this paper
• Clinical significance of post‐progression survival in lung cancer

  2017cites this paper
• A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

  2017cites this paper
• A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.

  2017cites this paper
• Intégration des mesures intermédiaires de survie dans les évaluations économiques en cancer du sein métastatique

  2017cites this paper
• Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials.

  2016cites this paper
• Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

  2016cites this paper
• First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials

  2016cites this paper
• An Introduction to Survival Statistics: Kaplan-Meier Analysis

  2016cites this paper
• Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.

  2016cites this paper
• HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

  2016cites this paper
• Sieve estimation in a Markov illness-death process under dual censoring.

  2016cites this paper
• How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software

  2016cites this paper
• Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer.

  2016cites this paper
• Mixed response and time-to-event endpoints for multistage single-arm phase II design

  2015influential citation
• Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504

  2015cites this paper
• Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

  2015cites this paper
• Design Issues in Randomized Clinical Trials of Maintenance Therapies.

  2015cites this paper
• Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

  2015cites this paper
• Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials

  2015cites this paper
• Bias in progression‐free survival analysis due to intermittent assessment of progression

  2015cites this paper
• A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data

  2015cites this paper
• Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

  2015cites this paper
• Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers

  2015cites this paper
• Clinically meaningful end points in the evolving treatment paradigm for radioactive iodine-refractory differentiated thyroid cancer

  2015cites this paper
• Clinical trial end points relevant to patients and society for rare cancers

  2015cites this paper
• Les critères de jugement des essais cliniques en cancérologie

  2014cites this paper
• Methods for Adjusting for Bias Due to Crossover in Oncology Trials

  2014cites this paper
• Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.

  2014cites this paper
• Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study

  2014cites this paper
• Endpoints in cancer clinical trials.

  2014cites this paper